ES2192136A1 - Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis. - Google Patents

Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis.

Info

Publication number
ES2192136A1
ES2192136A1 ES200200017A ES200200017A ES2192136A1 ES 2192136 A1 ES2192136 A1 ES 2192136A1 ES 200200017 A ES200200017 A ES 200200017A ES 200200017 A ES200200017 A ES 200200017A ES 2192136 A1 ES2192136 A1 ES 2192136A1
Authority
ES
Spain
Prior art keywords
osteoporosis
prevention
treatment
pharmaceutical compositions
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200200017A
Other languages
English (en)
Other versions
ES2192136B1 (es
Inventor
Lousame Dolores Blanco
Fernandez Alvaro Acebron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Italfarmaco SA
Original Assignee
Italfarmaco SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Italfarmaco SA filed Critical Italfarmaco SA
Priority to ES200200017A priority Critical patent/ES2192136B1/es
Priority to PCT/ES2003/000002 priority patent/WO2003055500A1/es
Priority to AU2003211610A priority patent/AU2003211610A1/en
Publication of ES2192136A1 publication Critical patent/ES2192136A1/es
Application granted granted Critical
Publication of ES2192136B1 publication Critical patent/ES2192136B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Composiciones farmacéuticas para el tratamiento o prevención de la osteoporosis. Composición farmacéutica oral, en forma de comprimidos masticables, granulados efervescentes o comprimidos efervescentes, estable y con características técnicas y organolépticas mejoradas, conteniendo una sal de iones fluoruro, vitamina D y calcio elemental en forma de sal, junto a cantidades adecuadas de excipientes farmacéuticamente aceptables, útiles para el tratamiento o prevención de la osteoporosis u otras enfermedades óseas, caracterizadas por la pérdida de masa ósea.
ES200200017A 2002-01-04 2002-01-04 Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis. Expired - Fee Related ES2192136B1 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES200200017A ES2192136B1 (es) 2002-01-04 2002-01-04 Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis.
PCT/ES2003/000002 WO2003055500A1 (es) 2002-01-04 2003-01-03 Composiciones farmaceuticas para tratamiento o prevencion de la osteoporosis
AU2003211610A AU2003211610A1 (en) 2002-01-04 2003-01-03 Pharmaceutical compositions for the treatment or prevention of osteoporosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200200017A ES2192136B1 (es) 2002-01-04 2002-01-04 Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis.

Publications (2)

Publication Number Publication Date
ES2192136A1 true ES2192136A1 (es) 2003-09-16
ES2192136B1 ES2192136B1 (es) 2005-03-16

Family

ID=8500130

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200200017A Expired - Fee Related ES2192136B1 (es) 2002-01-04 2002-01-04 Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis.

Country Status (3)

Country Link
AU (1) AU2003211610A1 (es)
ES (1) ES2192136B1 (es)
WO (1) WO2003055500A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045870A1 (es) * 2004-10-25 2006-05-04 Italfarmaco, S.A. Composiciones farmacéuticas bucodispersables

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20030194A1 (it) * 2003-07-17 2005-01-18 Menarini Int Operations Lu Sa Composizione farmaceutiche effervescenti contenenti
MXPA06013608A (es) 2004-05-24 2007-04-26 Nycomed Pharma As Particulado que comprende un compuesto que contiene calcio y un alcohol de azucar.
JP4996458B2 (ja) * 2004-06-01 2012-08-08 ニコメド ファーマ エイエス 活性物質としてカルシウム含有化合物を含み、咀嚼し、舐め、飲み込むことのできる錠剤
DE602006001295D1 (de) 2005-02-03 2008-07-03 Nycomed Pharma As Schmelzgranulation einer zusammensetzung mit einer calziumhaltigen verbindung
AU2006211023B2 (en) 2005-02-03 2012-05-24 Takeda Nycomed As Fast wet-massing method for the preparation of calcium-containing compositions
DE602006016641D1 (de) 2005-12-07 2010-10-14 Nycomed Danmark Aps Vorkompaktierte calciumhaltige zusammensetzungen
US7968130B2 (en) 2006-01-11 2011-06-28 Mission Pharmacal Co. Calcium-enriched food product
NZ592528A (en) 2008-11-17 2013-05-31 Nycomed Pharma As Improved dissolution stability of calcium carbonate tablets
WO2019004984A2 (en) * 2017-05-29 2019-01-03 Biofarma Ilac Sanayi Ve Ticaret A.S. PHARMACEUTICAL FORMULATION COMPRISING CHOLECALCIFEROL
WO2019138379A1 (en) * 2018-01-12 2019-07-18 Metimedi Pharmaceuticals Co., Ltd. Methods of treating chronic inflammatory diseases
CN109288811B (zh) * 2018-11-27 2021-02-09 正大制药（青岛）有限公司 一种艾地骨化醇软胶囊及其制备方法
CN109568279B (zh) * 2018-12-28 2020-10-20 正大制药（青岛）有限公司 一种氟骨化醇片剂及其制备方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3345265A (en) * 1963-10-09 1967-10-03 Kendall & Co Multiple layer tablet with calcium salt central core separated from soluble fluoride outer coating
EP0455503A1 (en) * 1990-05-04 1991-11-06 Colgate-Palmolive Company Composition for treating osteoporosis and hormonal imbalance
US5228445A (en) * 1990-06-18 1993-07-20 Board Of Regents, The University Of Texas System Demonstration by in vivo measurement of reflection ultrasound analysis of improved bone quality following slow-release fluoride treatment in osteoporosis patients
WO1996031215A1 (en) * 1995-04-03 1996-10-10 Bone Care International, Inc. Use of vitamin d2 or vitamin d4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
WO1997016193A1 (en) * 1995-10-27 1997-05-09 F. Hoffmann-La Roche Ag Pharmaceutical composition for treating osteoporosis
WO1999006051A1 (en) * 1997-07-30 1999-02-11 Menarini International Operations Luxembourg S.A. Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use
EP1051976A2 (en) * 1999-05-12 2000-11-15 Gador S.A. Use of bisphosphate for the treatment of osteogenesis imperfecta
WO2002028401A1 (en) * 2000-09-29 2002-04-11 Gregory Steiner Fluoride as a chemoprotective and chemotherapeutic agent for cancer in mammals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1177455A (zh) * 1996-09-26 1998-04-01 天津市红桥医院 加碘低钠钙盐

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3345265A (en) * 1963-10-09 1967-10-03 Kendall & Co Multiple layer tablet with calcium salt central core separated from soluble fluoride outer coating
EP0455503A1 (en) * 1990-05-04 1991-11-06 Colgate-Palmolive Company Composition for treating osteoporosis and hormonal imbalance
US5228445A (en) * 1990-06-18 1993-07-20 Board Of Regents, The University Of Texas System Demonstration by in vivo measurement of reflection ultrasound analysis of improved bone quality following slow-release fluoride treatment in osteoporosis patients
WO1996031215A1 (en) * 1995-04-03 1996-10-10 Bone Care International, Inc. Use of vitamin d2 or vitamin d4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
WO1997016193A1 (en) * 1995-10-27 1997-05-09 F. Hoffmann-La Roche Ag Pharmaceutical composition for treating osteoporosis
WO1999006051A1 (en) * 1997-07-30 1999-02-11 Menarini International Operations Luxembourg S.A. Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use
EP1051976A2 (en) * 1999-05-12 2000-11-15 Gador S.A. Use of bisphosphate for the treatment of osteogenesis imperfecta
WO2002028401A1 (en) * 2000-09-29 2002-04-11 Gregory Steiner Fluoride as a chemoprotective and chemotherapeutic agent for cancer in mammals

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
[en línea][recuperado el 21.02.2003] Recuperado de: EPO EPODOC Database & CN 1177455 A (HONGQIAO HOSPITAL) 01.04.1998 (resumen) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045870A1 (es) * 2004-10-25 2006-05-04 Italfarmaco, S.A. Composiciones farmacéuticas bucodispersables
ES2255429A1 (es) * 2004-10-25 2006-06-16 Italfarmaco, S.A. Composiciones farmaceuticas bucodispersables.
ES2255429B1 (es) * 2004-10-25 2007-08-16 Italfarmaco, S.A. Composiciones farmaceuticas bucodispersables.

Also Published As

Publication number Publication date
WO2003055500A8 (es) 2004-04-29
WO2003055500A1 (es) 2003-07-10
AU2003211610A1 (en) 2003-07-15
ES2192136B1 (es) 2005-03-16

Similar Documents

Publication Publication Date Title
ES2192136A1 (es) Composiciones farmaceuticas para el tratamiento o prevencion de la osteoporosis.
TW200637587A (en) Anti-caries oral care composition with xylitol
AU7566601A (en) Composition for the treatment and/or the prevention of osteoporosis and/or inflammatory joint diseases
TW200637581A (en) Anti-caries oral care composition with a chelating agent
WO2004098617A3 (en) Controlled release composition containing a strontium salt
DE60318193D1 (en) Phenethanolaminderivate
WO2004037768A3 (en) Phenethanolamine derivatives
TW200505837A (en) Novel compounds
WO2002014311A3 (en) Urea compounds and methods of uses
WO2004037773A8 (en) Phenethanolamine derivative for the treatment of respiratory diseases
TW200519075A (en) Novel compounds
UA86614C2 (ru) Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата
PL372809A1 (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
MXPA04009977A (es) Formulaciones de tramadol de liberacion sostenida con eficacia clinica durante 24 horas.
MX2007010017A (es) Composiciones de sal antitranspirante de aluminio o aluminio-zirconio de eficacia mejorada conteniendo sal(es) de calcio y betaina.
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
WO2002088100A3 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
WO2004017998A3 (en) Topical emulsion- gel composition comprising diclofenac sodium
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
PT1441688E (pt) Composições sólidas orais antitártaro e antiplaca
WO2007134158A3 (en) Granules comprising calcium carbonate, a binder and a porosity increasing agent, processes of manufacturing, use in therapy
IL180144A0 (en) Compositions comprising strontium and vitamin d and uses thereof
WO2005115414A3 (en) Orally-administrable compositions comprising stable amorphous calcium carbonate
BRPI0417416A (pt) composição de confeitaria de branqueamento de dentes oral sólida
WO2005082413A3 (en) Ciclesonide and glycopyrronium combination

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030916

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2192136B1

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20220426